{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-25-038737","form_type":"8-K","ticker":"ELVN","cik":"0001672619","company_name":"Enliven Therapeutics, Inc.","filed_at":"2025-03-13T23:59:59+00:00","discovered_at":"2026-05-14T18:03:04.390078+00:00","generated_at":"2026-05-24T21:24:24.445863+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Enliven Therapeutics Q4 2024 net loss $23.2M; cash $313.4M; pipeline milestones set for 2025","bullets":["Net loss $23.2M in Q4 2024 ($19.4M in Q4 2023); full year 2024 net loss $89.0M ($71.6M in FY2023).","Cash, cash equivalents and marketable securities $313.4M as of Dec 31, 2024; cash runway into mid-2027.","R&D expenses $20.7M in Q4 2024 ($17.9M Q4 2023); full year $80.8M ($64.6M FY2023).","ELVN-001 Phase 1 data expected mid-2025; ELVN-002 Phase 1 data expected H2 2025; FDA orphan drug designation.","First patient dosed in Japanese Phase 1 trial for ELVN-001; ELVN-002 combination trials enrolling."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-25-038737","json":"https://secwatch.observer/filing/0000950170-25-038737.json","markdown":"https://secwatch.observer/filing/0000950170-25-038737.md","text":"https://secwatch.observer/filing/0000950170-25-038737.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1672619/000095017025038737/0000950170-25-038737-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1672619/000095017025038737/elvn-20250313.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-24T21:24:24.445863+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}